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Abstract 
Background: To identify possible differences in cardiovascular (CV) risk among different insulin therapies, we per-
formed pre-specified meta-analyses across the clinical program for basal insulin peglispro (BIL), in patients rand-
omized to treatment with BIL or comparator insulin [glargine (IG) or NPH].
Methods: One phase 2 (12-week) and 6 phase 3 (26 to 78-week) randomized studies of BIL compared to IG or NPH, 
in patients with type 1 or type 2 diabetes, were included. The participants were diverse with respect to demographics, 
baseline glycemic control, and concomitant disease or medications, but treatment groups were comparable in each 
study. For any potential CV or neurovascular event, relevant medical information was provided to a blinded external 
clinical events committee (C5Research, Cleveland Clinic, Cleveland, OH, USA) for adjudication. Cox regression analysis 
was used to compare treatment groups. The primary endpoint was a composite of adjudicated MACE+ [CV death, 
myocardial infarction (MI), stroke, or hospitalization for unstable angina].
Results: The pooled population included 5862 patients in the safety evaluation, with randomization to BIL:IG:NPH of 
3578:2072:212. Mean age was 54.1 years, 27 % had type 1 diabetes, 56 % were male, and 88 % were white. Baseline 
demographic and clinical characteristics, including use of statins or other lipid-lowering drugs, were comparable 
between BIL and comparators. A total of 83 patients experienced at least 1 MACE+ and 70 patients experienced at 
least 1 MACE (CV death, MI, or stroke). Overall, there were no treatment-associated differences in time to MACE+ [haz-
ard ratio (HR) for BIL versus comparator insulin (95 % CI): 0.82 (0.53–1.27)] or MACE [0.83 (0.51–1.33)]. In 4297 patients 
with type 2 diabetes, there were 71 MACE+ events [HR: 1.02 (95 % CI: 0.63–1.65), p = 0.94]. In 1565 patients with 
type 1 diabetes, there were only 12 MACE+ [0.24 (0.07–0.85), p = 0.027]. There were no differences in all-cause death 
between BIL and comparators. Sub-group analyses did not identify any sub-population with increased risk with BIL 
versus comparator insulins.
Conclusions: Treatment with BIL versus comparator insulin in patients with type 1 diabetes or type 2 diabetes was 
not associated with increased risk for major CV events in the studies analyzed.
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Background
Diabetes mellitus is associated with an increased risk for 
cardiovascular disease (CVD). Both observational data 
and intervention trials support the concept that dyslipi-
demia, hypertension, and thrombogenic variables likely 
contribute to CVD risk in type 2 diabetes [1, 2]. Increas-
ing duration of diabetes is associated with increased CVD 
risk, as well as a likely need for insulin therapy. However, 
the effect of insulin use on CVD risk is unclear. In the 
ORIGIN trial, insulin glargine use versus standard of care 
in patients with impaired glucose tolerance or early dia-
betes was not associated with any CVD benefit or risk 
[3]. The UKPDS, a study in patients newly diagnosed 
with type 2 diabetes, suggested a CVD benefit in those 
individuals randomized to an intensive policy using oral 
glucose-lowering medications or insulin, compared to 
those who received the conventional policy [4–6]. Studies 
in patients with type 2 diabetes with more advanced dis-
ease have not shown benefits of intensive glucose control 
to reduce CVD risk [7–9]. In type 1 diabetes, the single 
large intervention trial (DCCT) and post-trial follow up 
(EDIC) compared intensive versus conventional insulin 
therapy and showed a reduction in CVD with intensive 
glycemic treatment in the long-term follow-up study [10, 
11].
By contrast, there are studies that suggest that insu-
lin therapy may be associated with increased CVD risk. 
Hypoglycemia was associated with increased mortality 
risk in the ACCORD trial [12], and a companion report 
by Miller and colleagues [13] reported that in patients 
on any insulin, the risk for hypoglycemia requiring the 
help of another person increased by more than fourfold. 
Siraj and associates used the ACCORD data to analyze 
whether insulin dose was associated with increased car-
diovascular mortality [14]. In univariate analyses there 
was an association, but this association was no longer 
statistically significant after adjustment for baseline 
covariates. Whereas the mechanism by which insulin 
may contribute to CVD risk or mortality is unclear, sev-
eral investigators have shown that insulin-associated 
hypoglycemia is also associated with cardiac arrhythmias 
[15–18]. Comparisons among insulin analogs that may 
have greater efficacy or reduced risk for hypoglycemia 
are limited. Only recently was a meta-analysis for CV 
events performed in the phase 3 insulin degludec trials 
versus other insulins. In this meta-analysis there were 80 
MACE+ [CV death, nonfatal myocardial infarction (MI), 
nonfatal stroke, and unstable angina with hospitalization] 
with a HR 1.097 (95 % CI of 0.681, 1.768), and 54 MACE 
(MI, stroke, CV death) with a HR 1.393 (95 % CI 0.757–
2.565) [19]. The current report extends the data on CVD 
events with different insulin analogs.
Basal insulin peglispro (BIL) is a novel basal insulin 
with a large hydrodynamic size [20]. In phase 1 studies, 
BIL was shown to have slower absorption from the site 
of injection, slower clearance from the circulation, and a 
prolonged duration of action compared to conventional 
basal insulin [21, 22]. In addition, BIL was shown to have 
reduced peripheral activity, resulting in hepato-preferen-
tial action [23, 24].
In order to identify possible differences in CV risk 
among different insulin therapies, pre-specified meta-
analyses for CVD events were performed across the clini-
cal program using an integrated database of a phase 2 
study and 6 phase 3 studies with active comparators. The 
primary outcome variable was the composite of major 
adverse CV events (MACE+) based on independent 
adjudication. Secondary outcome endpoints included the 
composite of adjudicated MACE, as well as each indi-




The phase 3 program for BIL included six studies with 
an active comparator; two studies in type 1 diabetes 
(N = 1569, all randomized patients; 1565 in the safety 
evaluation) and 4 studies in type 2 diabetes (N = 4014, 
all randomized patients; 4009 in the safety evalua-
tion), with three studies on basal insulin only and one 
study on basal-bolus insulin [25–30]. Three of the stud-
ies were double-blind [26–28]. The integrated safety 
analyses included these 6 phase 3 studies and 1 phase 
2 study in type 2 diabetes with an active comparator 
(N  =  289, all randomized patients, 288 in the safety 
evaluation) [31], each of which had a pre-defined CV 
event adjudication process. Adjudication was not per-
formed in a phase 2 Study in patients with type 1 dia-
betes since that study was completed prior to FDA 
request for adjudication of CV events in patients with 
type 1 diabetes. All of the studies in the meta-analysis 
were conducted in accordance with the International 
Conference on Harmonization Guidelines for Good 
Clinical Practice and the Declaration of Helsinki. All 
patients signed an informed consent document, and 
the protocols and consent documents were approved 
by local ethical review boards prior to study initiation. 
The studies were registered at clinicaltrials.gov as fol-
lows: NCT01435616, NCT01468987, NCT01481779, 
NCT01454284, NCT01582451, NCT01790438, 
NCT01027871.
In the BIL clinical trials, potential CV events were 
identified through several different approaches including 
investigator-identified, customized strategy based on the 
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Medical Dictionary for Regulatory Activities (MedDRA) 
search terms, or based on review of adjudication pack-
age or severe adverse events/adverse events. If a potential 
event was identified by any of these approaches, a request 
to provide specific information was sent to the site and 
any materials related to a possible event, such as the rel-
evant clinical details and associated laboratory tests, 
electrocardiograms, and imaging studies, were forwarded 
to the CEC (C5Research, Cleveland Clinic, Cleveland, 
OH, USA) for adjudication. The CEC blindly adjudicated 
the events based on a pre-specified event definition and 
rendered an assessment as to whether the case repre-
sented a confirmed event, a non-event [for example, not 
MACE+  or transient ischemic attack (TIA)] or lacked 
sufficient documentation for confirmation of an event. 
All TIAs were adjudicated to insure that no stroke event 
was missed.
Statistical analysis
The primary outcome of MACE+ was analyzed using a 
Cox proportional hazard model with independent vari-
ables of treatment group (BIL versus comparator insu-
lins) and type of study population (type 1 diabetes, type 
2 diabetes insulin naïve, and type 2 diabetes previously 
treated with insulin), with Firth bias correction [32]. The 
Kaplan–Meier curve for the cumulative probability of 
events was estimated for each treatment group. Similar 
analyses were conducted for the secondary CV endpoints 
of MACE and individual MACE+  components, as well 
as all-cause death. As supportive analyses, the treatment 
incidence rate (per 100 patient-years) was compared 
between treatments using the Mantel–Haenszel test 
stratified by study population.
To examine if the treatment effect was different across 
certain risk factors, subgroup analyses were performed 
using a Cox regression model with independent vari-
ables of treatment group, subgroup and treatment-by-
subgroup interaction for the following variables: type 
of diabetes, sex, age (>65,  ≤65  years), disease dura-
tion (>10,  ≤10  years), prior history of CVD, prior his-
tory of hypertension, lipid-lowing medication use, BMI 
(≥30, <30 kg/m2), and race (white, not white).
Per the modified intent-to-treat principle, the analysis 
period was from first dose of study drug to end of follow-
up; any events captured from first dose of study drug to 
end of study (including the 4-week follow up period, as 
well as the period after early termination of study drug 
but staying in the study) were included in the CV risk 
analysis. Time to first event was calculated from the date 
of first dose of the study drug to the date of first event 
occurrence. Patients who discontinued the study early 
or completed the study without developing events were 
right-censored at the date of the last visit.
Results
A total of 5862 patients from seven clinical trials were 
included in the meta-analysis, 3578 who were rand-
omized to treatment with BIL, 2072 to IG, and 212 to 
NPH. Baseline demographic and clinical characteris-
tics of the overall patient population is given in Table 1; 
approximately 27  % had type 1 diabetes, mean diabetes 
Table 1 Patient demographic and baseline characteristics
Mean ± SD unless otherwise specified. p value >0.05 unless specified
* p = 0.031





Type 1 diabetes, n (%) 610 (26.7) 959 (26.8)
Age, years 54.2 ± 13.3 54.0 ± 13.3
Male,  % 58.0 54.7*
Race, n (%)
 American Indian/Alaska native 23 (1.0) 37 (1.0)
 Asian 102 (4.5) 182 (5.1)
 Black/African American 120 (5.2) 182 (5.1)
 Multiple 21 (0.9) 29 (0.8)
 Native Hawaiian/Pacific Islander 4 (0.2) 7 (0.2)
 White 2018 (88.2) 3143 (87.8)
Hispanic or Latino, n (%) 332 (14.5) 580 (16.2)
Region, n (%)
 North America 1019 (44.5) 1611 (45.0)
 European Union 834 (36.5) 1282 (35.8)
 Japan 42 (1.8) 70 (2.0)
 Other 393 (17.2) 621 (17.3)
BMI, kg/m2 30.7 ± 5.7 30.6 ± 5.7
Body weight, kg 88.6 ± 19.5 87.7 ± 19.1
Duration of diabetes, years 14.2 ± 9.4 13.8 ± 9.1
HbA1c,  % 8.2 ± 1.1 8.2 ± 1.1
Hypertension, n (%) 1588 (69.4) 2458 (68.6)
Triglycerides, mg/dL 135 ± 86 139 ± 93
Total cholesterol, mg/dL 176 ± 38 177 ± 39
LDL-C, mg/dL 97 ± 33 98 ± 33
HDL-C, mg/dL 52 ± 16 52 ± 16
History of myocardial infarction,  
n (%)
93 (4.2) 149 (4.4)
History of coronary revasculariza-
tion, n (%)
83 (3.8) 121 (3.6)
History of coronary artery bypass 
graft, n (%)
56 (2.6) 92 (2.7)
Lipid lowering medication, n (%) 1274 (55.7) 1965 (54.8)
 Statin 1165 (50.9) 1787 (49.9)
 Non-statin 316 (13.8) 499 (13.9)
Smoking status, n (%)
 Never used 1279 (58.3) 2013 (59.4)
 Current used 340 (15.5) 507 (15.0)
 Ever used 575 (26.2) 867 (25.6)
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duration was 14 years, and 88 % were white. There were 
slightly more men in the comparator insulin group.
The studies provided 3278 patient-years of exposure 
to BIL and 2016 patient-years of exposure to compara-
tor insulins in three patient groups: type 1 diabetes, type 
2 diabetes on a basal-bolus regimen, and type 2 diabetes 
on basal insulin only. Results of the adjudication pro-
cesses are summarized in the Additional file  1: Table 
S1. In addition to 125 investigator-reported potential 
events resulting in 93 adjudicated events, use of Med-
DRA search terms identified an additional 124 poten-
tial events, resulting in eight adjudicated events (MI: 3; 
unstable angina 3; stroke: 1; TIA: 1).
A total of 83 patients experienced at least one com-
ponent of the MACE+  composite and 70 patients 
experienced at least one component of the MACE 
composite. The Kaplan–Meier curves for time to first 
MACE+ and MACE are shown in Fig. 1a and b, respec-
tively. The overall incidence rates per 100 patient-years 
for MACE +  were 1.8 and 1.4 for treatment with com-
parator insulins and BIL, respectively, and for MACE 
were 1.5 and 1.2 for treatment with comparator insulins 
and BIL. The Cox regression analysis showed that treat-
ment with BIL versus comparator insulins in the overall 
patient population had a HR (95 % CI) of 0.82 (0.53–1.27) 
for MACE+  and 0.83 (0.51–1.33) for MACE (Fig.  1c). 
Event rates and HR for the individual components of 
MACE+ (CV death, stroke, MI, or unstable angina) and 
for all-cause death for BIL and comparator insulin groups 
are shown in Fig.  1c. In supportive analyses, the differ-
ences in incidence rates (BIL minus comparator insulin) 
were −0.31 (−1.02 to 0.41) events per 100 patient-years 
for MACE+  and −0.23 (−0.88 to 0.42) events per 100 
patient-years for MACE.
The incidence rates for adjudicated MACE+ or MACE 
by individual study or patient group were not statistically 
different between BIL and comparator insulin treatment, 
except for patients with type 1 diabetes (Additional file 1: 
Table S2). The HR for MACE+  for patients with type 1 
diabetes (integrated results of two studies) for treatment 
with BIL versus comparator insulin was 0.24 [95  % CI: 
0.07–0.85], nominal p = 0.027. The HR for MACE+  for 
patients with type 2 diabetes (integrated results of five 
studies) showed no statistically significant difference in 
risk for patients treated with BIL versus comparator insu-
lin [1.02 (0.63–1.65), p = 0.94].
The results for the individual studies (Fig. 2) showed no 
increased risk for CVD in any patient population stud-
ied, including in type 1 diabetes and in three populations 
of patients with type 2 diabetes (insulin naïve with basal 
insulin treatment, previously on insulin with basal insu-
lin treatment, and previously on insulin with basal-bolus 
treatment). Sub-group analyses, performed to look for 
differences in CVD risk in the overall study population by 
age, sex, duration of diabetes, and other characteristics, 
showed no evidence of increased risk with BIL versus 
comparator insulin in any sub-group (Fig. 3).
Discussion
The current meta-analysis was performed to assess 
whether there might be any cardiovascular risk asso-
ciated with a novel hepato-preferential basal insulin 
(based on less peripheral insulin effects) when compared 
to conventional insulins (glargine and NPH) in patients 
with type 1 or type 2 diabetes. This approach of analyz-
ing data from phase 3 trials was consistent with that used 
in drug development to help inform CV risk. The current 
data demonstrated that there was no apparent increased 
MACE+ or all-cause mortality with BIL versus compara-
tor insulin, although the upper bound of the 95 % CI in 
patients with type 2 diabetes did not meet the FDA guid-
ance on oral glucose lowering agents for submission 
without a CV outcomes trial [33]. These analyses add to 
the body of data on insulin and CVD risk.
Few randomized trial data exist on the effects of insulin 
on CVD outcomes. DIGAMI 1 and DIGAMI 2 evaluated 
insulin therapy (using glucose-insulin-potassium infu-
sions) after a myocardial infarction and the studies came 
to opposite conclusions (DIGAMI 1: benefit; DIGAMI 2: 
no benefit) [34, 35]. Heart 2D assessed the effects of pran-
dial insulin therapy versus basal insulin on CV events 
and did not show a difference [36], except in a subset of 
patients over the age of 65 [37]. ORIGIN compared insu-
lin glargine to standard of care in patients with impaired 
glucose tolerance or diabetes mellitus and did not show 
any difference in CVD events [3]. In the only other large 
data set of a basal insulin versus conventional insulin, 
the meta-analysis of phase 2/3 insulin degludec program 
reported MACE+ (current manuscript definition) with a 
HR of 1.097 (95 % CI: 0.681–1.768) and MACE with a HR 
of 1.393 (0.757–2.565) [19].
Analyses from observational data sets on possible rela-
tionships of types of insulin or total insulin dose with CV 
events or mortality are also limited. Three retrospective 
studies using database information have compared insu-
lin types and CVD outcomes, and Siraj has performed 
a retrospective analysis of total insulin dose and CVD 
mortality [14, 38–40]. Kollhorst and colleagues analyzed 
17,523 patients with type 2 diabetes from a German data-
base who initiated NPH, a long-acting insulin analog (IG, 
detemir), or premixed insulins. In the primary analy-
sis, premixed insulins were associated with higher risk 
for MI than long-acting analogs, but no differences were 
found between NPH and long-acting analogs. Propensity 
matched analyses showed no differences in MI among the 
3 insulin groups [38]. Rhoads and associates evaluated 
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Fig. 1 a, b Kaplan–Meier curves for time to first MACE+ and MACE, respectively, in the meta-analysis. c, d Hazard ratios (HR) and 95 % CI for risk 
of MACE+, MACE, components, and all-cause death for treatment with BIL versus comparator insulin in the meta-analysis (c all patients; d type 2 
diabetes). Comp comparator insulin; BIL basal insulin peglispro
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20,191 patients from an American national administrative 
claims data base (of more than 30 managed health care 
plans) who started NPH (N = 5461) or IG (N = 14,730). 
In Cox proportional hazards and Poisson regression mod-
els as well as with propensity score methods, patients 
treated with NPH were more likely to have an MI than 
those on IG [39]. Juhaeri and colleagues evaluated 65,619 
patients from the PharMetrics integrated claim database 
who were on 4 different types of insulin regimens: (1) IG, 
(2) intermediate or long-acting insulins, excluding IG, (3) 
IG and another insulin, or (4) any other insulin regimen 
(rapid/short acting, premix, or 2 or more non-IG types). 
The authors did extensive analyses and concluded that use 
of IG might be associated with reduced risk for MI, but 
this did not reach statistical significance [40]. Whereas 
these data sets may be interpreted as suggesting that there 
may be differences among insulins with regard to CVD 
risk, the findings are neither consistent nor compelling. 
Siraj and coworkers studied the effects of insulin dose 
on the risk for mortality in the well-characterized cohort 
of patients from the ACCORD trial. Whereas there was 
a relationship between insulin dose and CV mortality in 
unadjusted models, with full adjustment for other CV risk 
factors, there was no relationship between total insulin 
dose and CV mortality [14].
In the assessment of CVD risk in patients on insulin, 
it is important to consider potential risk factors for CVD 
that may influence outcome. What follows is a discussion 
of potential CV risk factors that may be considered when 
patients treated with BIL were compared to those treated 
with conventional insulins. We briefly discuss variables 
in which there are differences between BIL and compara-
tor insulins [triglycerides (TG), liver fat content (LFC), 
hypoglycemia, body weight] and try to put these changes 
into clinical context from observational and clinical trial 
data. We briefly summarize selected reports on favorable 
biomarker profiles with conventional insulin administra-
tion. However, there is no corresponding biomarker data 
in the BIL program.
In phase 2 studies of BIL in which patients had all 
been on insulin prior to randomization to BIL versus 
Fig. 2 a Hazard ratios (HR) and 95 % CI for risk of MACE+ for treatment with BIL versus comparator insulin in the individual studies. BB basal-bolus 
insulin therapy, BIL basal insulin peglispro, BO basal only insulin therapy, N insulin naïve prior to study, P taking insulin prior to study, T1 type 1 diabe-
tes, T2 type 2 diabetes
Fig. 3 Hazard Ratios for MACE+ by subgroup. BIL basal insulin peglis-
pro; DM diabetes mellitus; CVD cardiovascular disease
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IG, BIL-treated patients had an increase from baseline 
of serum TG, while IG-treated patients did not [least 
squares mean (LSM) difference for type 1 diabetes: 
29 mg/dL; for type 2 diabetes: 27 mg/dL] [31, 41]. In the 
BIL phase 3 program, patients who had previously been 
treated with conventional insulins and were randomized 
to BIL also had an increase from baseline of TG levels 
compared to those randomized to IG [LSM difference 
(BIL-IG), change from baseline to week 26 for type 1 dia-
betes studies: 20–24 mg/dL; for type 2 diabetes studies: 
25–27 mg/dL] [25, 26, 28, 30]. However, in insulin naïve 
patients, those randomized to BIL had no increase in 
TG over the first 26 weeks of BIL treatment, while those 
treated with IG or NPH had a decrease in TG levels [27, 
29, 42]. Thus the observed increase in TG levels appears 
to be predominantly the result of withdrawal from con-
ventional insulin, although some direct effect of BIL can-
not be entirely excluded. Whether TG levels contribute to 
CVD risk cannot be assessed from these meta-analyses.
In the BIL phase 3 program where BIL was compared 
to IG, patients had a mean decrease in HDL-C [LSM 
difference (BIL-IG), change from baseline to week 26 
for type 1 diabetes studies: −1 to −3 mg/dL; for type 2 
diabetes studies: 0 to −2 mg/dL]. Over the same period, 
patients in type 1 diabetes studies had a mean increase 
in LDL-C (LSM difference, change from baseline to week 
26: 1–5 mg/dL), while patients in type 2 diabetes studies 
had a mean decrease (LSM difference, change from base-
line to week 26: −1 to −5 mg/dL) [25–28, 30].
LFC at baseline was higher in patients with type 2 dia-
betes than in patients with type 1 diabetes [43]. In insu-
lin naïve patients there was no increase in mean LFC in 
patients treated with BIL, while mean LFC declined in 
patients treated with IG. In patients previously treated 
with insulin, LFC remained unchanged with IG treat-
ment, but increased in patients randomized to BIL [43]. 
Thus the observed increase in LFC appears to be pre-
dominantly the result of withdrawal from conventional 
insulin, although some direct effect of BIL cannot be 
entirely excluded. Although there are reported asso-
ciations of NAFLD with CVD in diabetes patients, there 
are no large intervention studies demonstrating that 
changes in LFC are associated with changes in the CVD 
risk. Whether LFC contributes to CVD risk cannot be 
assessed from these meta-analyses.
Hypoglycemia has been associated with a risk for all-
cause mortality events and CVD events [12, 44], but 
whether it is causally related is still uncertain. Overall, 
BIL was quite consistently associated with reduced risk 
for nocturnal hypoglycemia [45]; total hypoglycemia was 
comparable in patients who were treated with basal insu-
lin only; in patients on basal-bolus insulin therapy, there 
was an increase in daytime hypoglycemia as well as total 
hypoglycemia with BIL [25, 26, 28]. As with triglycerides, 
the number of MACE+ was too small to do formal analy-
ses of any association of hypoglycemia with MACE+.
In the BIL phase 3 program, patients in type 1 dia-
betes studies lost weight in response to BIL and gained 
weight in response to IG (LSM difference [BIL-IG], 
change from baseline to Week 26: −1.3 to −1.9 kg) [25, 
26]. For patients in type 2 diabetes studies, those tak-
ing BIL gained less weight compared to those taking IG 
(LSM difference, change from baseline to week 26: −0.3 
to −1.0 kg) [27, 28, 30]. The effects of weight change on 
CVD risk are still uncertain. The order of magnitude of 
the changes in the BIL program is unlikely to affect CV 
risk. This conclusion derives from the observations from 
the Look AHEAD study in which even greater weight dif-
ferences, maintained for longer periods, were not associ-
ated with favorable effects on CV outcomes [46].
Other conventional insulins, including IG, have been 
associated with potentially favorable effects on biomark-
ers associated with CVD. For example, Chauduri and col-
leagues have summarized potential beneficial effects of 
insulin on inflammatory markers [47], Oikonomou and 
associates have reported increased circulating endothe-
lial progenitor cells with IG and NPH treatment [48], 
and other investigators have reported favorable effects 
of such things as metalloproteinases and adhesion mol-
ecules [49]. However, these observations of potentially 
favorable effects of conventional insulins on CVD risk 
markers have not yet been confirmed by clinical out-
comes data [47], especially comparisons among different 
insulins. These novel biomarkers were not evaluated in 
the BIL phase 2/3 program.
Whether meta-analyses of phase 3 program data are 
sufficient to inform CV risk can be addressed by compar-
ing meta-analyses of phase 2/3 data from 3 glucose-lower-
ing medications in which randomized placebo-controlled 
(plus standard of care) CVOTs have also been performed: 
SAVOR [50] (saxagliptin), EXAMINE [51] (alogliptin), 
and TECOS [52] (sitagliptin). Each of the development 
programs had done meta-analyses of the CV events from 
the phase 2/3 programs. The phase 2/3 meta-analysis 
results of MACE (41 events) with saxagliptin versus pla-
cebo in 4607 patients showed a HR of 0.45 (95 % CI: 0.24–
0.83) [53], while the prospective trial (SAVOR) in 16,492 
patients with a median follow up of 2.1 years reported a 
MACE HR of 1.00 (95 % CI: 0.89–1.12) with 1222 events 
[50]. The phase 2 and 3 meta-analysis of MACE with 
alogliptin versus placebo in 4168 patients showed a HR of 
0.635 (95 % CI: 0.0–1.41) with only 23 events [54], while 
the HR from the EXAMINE trial in 5380 patients and 
a median follow up of 18 months reported a HR of 0.96 
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(upper bound of the 95 % CI = 1.16) with 621 MACE [51]. 
The phase 2 and phase 3 meta-analysis of MACE with 
sitagliptin versus placebo or active comparator in 14,611 
patients with 78 events showed an adjusted incidence rate 
ratio of 0.83 (95 % CI: 0.53–1.30) [55], while the HR from 
the TECOS trial in 14,671 patients for MACE (the sec-
ondary composite outcome,1211 patients) was 0.99 (95 % 
CI: 0.89–1.11) [52].
Even though the BIL phase 2/3 program had 70 MACE 
and 83 MACE+  , the disparities between consistently 
lower hazard or risk ratios in meta-analyses than in the 
three CVOTs of dipeptidyl peptidase-4 inhibitors high-
light the limitations of meta-analyses. The FDA guidance 
does suggest that both phase 2 and 3 programs select 
patients who are at “high” CV risk. In general, phase 3 
programs include patients at low risk for CVD because 
of the need for monotherapy comparisons (and usually 
shorter duration of diabetes), renal function restrictions 
(such as when metformin is a comparator or background 
therapy), and the exclusion of patients with acute coro-
nary syndromes or need for insulin. Patients with type 
2 diabetes who require insulin therapy are generally at 
higher CV risk than those who require oral agents only 
[56]. Whether the meta-analyses of patients at higher risk 
for CVD based on need for insulin will be more informa-
tive than meta-analyses of programs of oral glucose-low-
ering drugs is uncertain.
Limitations of the meta-analyses for the BIL program 
beyond the general meta-analysis concerns noted above 
include the fact that trials of 26–78  weeks may be too 
short to address CVD risk. All trials had an active com-
parator (IG or NPH), so benefits/risks of the compara-
tor insulins versus non-insulin therapies on CVD risk 
cannot be assessed. Finally, the small number of CVD 
events and the short duration of the phase 3 studies limit 
our ability to determine whether differences in putative 
CVD risk factors between BIL and comparator insulins 
(e.g., lipids, hypoglycemia, body weight, LFC) affect these 
observations.
Strengths of the phase 3 program include the large 
number of patients exposed to BIL (N = 3578) and com-
parator insulins (N  =  2284), the fact that 3 of the tri-
als were double-blind, and the careful identification of 
potential CVD events and blinded adjudication.
Conclusions
Meta-analyses of MACE and MACE+  in patients with 
diabetes treated with BIL versus comparator insulins do 
not suggest that BIL is associated with increased CV risk. 
These results must be interpreted in the context of the 
limitations of phase 2/3 data to adequately assess CVD 
risk, as well as the current uncertainty as to whether 
differences among insulins or the total insulin dose is 
likely to be associated with CV risk.
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